NCT03041688View on ClinicalTrials.gov

Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

February 8, 2018

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Acute Myeloid LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaSecondary Acute Myeloid Leukemia
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

DRUG

Decitabine

Given IV

DRUG

Navtemadlin

Given PO

DRUG

Venetoclax

Given PO

Trial Locations (13)

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

23298

VCU Massey Comprehensive Cancer Center, Richmond

40536

University of Kentucky/Markey Cancer Center, Lexington

43210

Ohio State University Comprehensive Cancer Center, Columbus

90033

Los Angeles General Medical Center, Los Angeles

USC / Norris Comprehensive Cancer Center, Los Angeles

91010

City of Hope Comprehensive Cancer Center, Duarte

91105

Keck Medical Center of USC Pasadena, Pasadena

95817

University of California Davis Comprehensive Cancer Center, Sacramento

02114

Massachusetts General Hospital Cancer Center, Boston

02115

Brigham and Women's Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH